

Review of: "Italian Position Paper (SIPMO-SICMF) on Medication-Related Osteonecrosis of the Jaw (MRONJ)"

Keisuke Seki¹

¹ Nihon University

Potential competing interests: No potential competing interests to declare.

As the authors state in their conclusion, the evidence is still in the process of being established in this area. However, this position paper summarizes the evidence to date, and the opinions seem to be generally consistent with the latest position papers from other countries. In particular, the subgroup classification of lesions is excellent and easy for medical professionals to understand. On the other hand, the interpretation of stage 0 seems to be different from other papers, and it is necessary to pay attention to avoid confusing the medical staff by the supplementary explanation. Descriptions regarding prophylactic drug holiday should be explained in figures, as textual descriptions can be detailed but may be difficult to understand (P.30). New findings on implant treatment are information that every reader wants to know. Evidence is also gathering that existing implants can trigger MRONJ development, and this should be emphasized and updated information should be included. In the section on surgical treatment (P.35), a more detailed description is desirable with regard to margin specification of the surgical resection area.